|
Aim: Cannabis use disorder (CUD) remains an intractable problem. Three recently completed randomized, controlled clinical trials investigating different pharmacological interventions for CUD were separately analyzed.
Methods: The outcome Marijuana Use, measured by the number of abstinent days (recorded by Timeline Followback) per week, was categorized into three groups: High Use (0-2 abstinent days), Medium Use (3-5 abstinent days), and Low Use (6-7 abstinent days), and analyzed by longitudinal, multinomial logistic regression in 3 clinical trials.
Results: In all three trials there were no significant treatment vs PBO differences in abstinence rates at the end of the studies. However, all three trials exhibited a similar temporal pattern in reduction of categorized Marijuana Use: Starting from about week 5, the odds of Medium Use (compared to High Use) were significantly higher for all three treatments compared to PBO.
Conclusions: While study-end abstinence rates have been a standard treatment outcome for CUD trials, reduction from high to medium use has not been standardly assessed, even though this could potentially illuminate the additional benefits of CUD medication.
|
